2 febbraio 2024;17(2):199 Allison KC, Chao AM, Bruzas MB, McCuen-Wurst C, Jones E, McAllister C, et al
Purpose ELIXA was conducted to assess the cardiovascular safety of once-daily subcutaneously injected lixisenatide 20 mcg (Adlyxin) by documenting non-inferiority, as well as superiority, for the primary composite outcome of non-fatal myocardial infarction, non-fatal stroke, CV death, or hospitalization for unstable angina (4-point MACE) in an adult population with T2DM and extremely high CV risk
This is due to the obesity and diabetes management centers
Criminal Team Leader David S
It is available to us in our diets, derived almost exclusively from proteins, and yet only 2 of the 20 amino acids normally present in proteins contains sulfur